Products for Research Use Only

Carbacyclin

CAT: 0804-HY-112322-01Size: 100 μg (2.85 mM x 100 μL in Methyl Acetate)Dry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112322-01Size:100 μg (2.85 mM x 100 μL in Methyl Acetate)
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.
CAS Number
69552-46-1
Product Name Alternative
Carbaprostacyclin; Carba-PGI2
UNSPSC
12352211
Hazard Statement
H302, H312, H332
Target
PPAR; Prostaglandin Receptor
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Carbacyclin.html
Concentration
2.85 mM * 100 μL in Methyl acetate
Purity
99.0
Smiles
O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)CCCCC)[C@@]2([H])C\1
Molecular Formula
C21H34O4
Molecular Weight
350.49
Precautions
H302, H312, H332
References & Citations
[1]Takasuka M, et al. FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor agonist (U-46619), prostaglandin (PG) E2, PGD2, PGF2 alpha, prostacyclin receptor agonist (carbacyclin), and their related compounds in dilute CCl4 solution: structure-activity relationships. J Med Chem. 1994 Jan 7;37 (1) :47-56.|[2]Whittle BJ, et al. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 1980 Apr;19 (4) :605-27.|[3]Kuroda T, et al. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway. J Mol Cell Cardiol. 2007 Jul;43 (1) :54-62.
Shipping Conditions
Blue Ice
Storage Conditions
Solution, -20°C, 2 years
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IP